LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

Fechado

4.5 -0.88

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.49

Máximo

4.52

Indicadores-chave
By Trading Economics
Rendimento	-29K -20M
Vendas	701K 2M
EPS	-0.15
Margem de lucro	-993.186
Funcionários	69
EBITDA	-2.5M -22M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+129.65% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-13M 620M
Abertura anterior	5.38
Fecho anterior	4.5

Aclaris Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de mai. de 2026, 08:24 UTC

Grandes Movimentos do Mercado

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 de mai. de 2026, 21:22 UTC

Ganhos

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:01 UTC

Conversa de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 de mai. de 2026, 14:43 UTC

Conversa de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 de mai. de 2026, 14:15 UTC

Conversa de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 de mai. de 2026, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

25 de mai. de 2026, 12:58 UTC

Conversa de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 de mai. de 2026, 12:56 UTC

Conversa de Mercado

Ganhos

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 de mai. de 2026, 12:34 UTC

Conversa de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 de mai. de 2026, 12:10 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Delivery Hero's Assets Look Strategic -- Market Talk

25 de mai. de 2026, 11:00 UTC

Conversa de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 de mai. de 2026, 10:19 UTC

Conversa de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 de mai. de 2026, 10:05 UTC

Ganhos

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 de mai. de 2026, 10:04 UTC

Ganhos

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 de mai. de 2026, 10:03 UTC

Ganhos

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 de mai. de 2026, 10:02 UTC

Ganhos

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 de mai. de 2026, 10:01 UTC

Ganhos

Tenaga Nasional 1Q Net Up 3.7% on Year

25 de mai. de 2026, 10:00 UTC

Ganhos

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q EPS MYR0.1883

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Rev MYR17.1B

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Net MYR1.1B

25 de mai. de 2026, 09:38 UTC

Conversa de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 de mai. de 2026, 08:55 UTC

Conversa de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparação entre Pares

Variação de preço

Aclaris Therapeutics Inc Previsão

Preço-alvo

By TipRanks

129.65% parte superior

Previsão para 12 meses

Média 10.38 USD 129.65%

Máximo 16 USD

Mínimo 4 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Aclaris Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Aclaris Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.